Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

Jiangsu Alphamab Biopharmaceuticals Co., Ltd. is a biopharmaceutical company founded in 2015, focusing on the development, production, and commercialization of innovative oncology drugs. It was listed on the Main Board of the Hong Kong Stock Exchange on December 12, 2019 (stock code: 09966.HK). The company has developed core technology platforms including single-domain antibodies, bispecific antibodies, site-specific glycosylation conjugation, linker-payload, dual-payload antibody-drug conjugates, and high-concentration subcutaneous formulations. Its product pipeline includes approved drugs such as Envida (KN035) and Ennituo (KN026), as well as multiple clinical-stage candidates.

Jiangsu Alphamab Biopharmaceuticals Co., Ltd. was founded in 2015. On December 12, 2019, the company was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 09966.HK). The company focuses on the development, production, and commercialization of innovative oncology drugs. It has established core technology platforms including single-domain antibodies, bispecific antibodies, site-specific glycosylation conjugation, linker-payload, dual-payload antibody-drug conjugates, and high-concentration subcutaneous formulations. The company's product pipeline includes approved drugs such as Envida (KN035) and Ennituo (KN026), as well as multiple clinical-stage candidates.

1. 1康宁杰瑞alphamabonc.com
2. 2公司简介-康宁杰瑞alphamabonc.com
3. 3董事会-康宁杰瑞alphamabonc.com
4. 4产品概况-康宁杰瑞alphamabonc.com
5. 5Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (China)wikidata.org